

CARLOS MOEDAS

Member of the European Commission

15 JAN. 2018

Brussels.

Ares S(2017)6879002

Dear Ms Galli,

I would like to thank you for your e-mail of 4 December 2017 with the enclosed 'Open Letter to increase the social impact and public return of FP9 medical R&I investments'. I share your goal to further increase the impact of EU-funded health research and generate significant public return on investment such as research and innovation.

FP7 and Horizon 2020 projects have contributed to major advances for public health, and we aim to increase this impact further in the current and future EU framework programmes. In particular, the Health Directorate in the Directorate-General for Research and Innovation has engaged on this issue with you and your colleagues in two recent events in the European Parliament on 11 July on 'R&D in Health: Pulling together efforts and ensuring public return for society' and on 26 September on 'Alternatives to monopolies as a mechanism to fund biomedical R&D'.

I am also pleased that a meeting is organised between you and your colleagues and our services on 29 January 2018 to continue this discussion on concrete proposals of how to get the most out of our public investment into health research and innovation. I look forward to hearing about the outcomes of this meeting.

Yours sincerely,

A handwritten signature in black ink, consisting of a large, fluid, cursive 'C' followed by a series of loops and a vertical line ending in a horizontal stroke.

Carlos MOEDAS

Ms Viviana Galli
Coordinator
European Alliance for Responsible R&D and Affordable Medicines
c/o EPHA
Rue de Trèves 49
BE - 1000 Brussels